Has Simon Ordonez received payments from drug or device companies?

Yes. Drug and device makers reported $10,221 in general payments to Simon Ordonez across 492 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Simon Ordonez did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Simon Ordonez come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Simon Ordonez

Physician Assistant · Dallas, TXNPI 1891145884

Payments from drug & device makers

$10,221in general payments, 2019–2025

Across 492 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
Otsuka America Pharmaceutical, Inc.$661
Axsome Therapeutics, Inc.$611
Neurocrine Biosciences, Inc.$579
Takeda Pharmaceuticals U.S.A., Inc.$563
plus $5K from 25 others

What the payments were for

Food & beverage$10,14499%
Education$771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	123	$1,359
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	37	$1,041
Otsuka America Pharmaceutical, Inc.	30	$661
Axsome Therapeutics, Inc.	16	$611
Neurocrine Biosciences, Inc.	14	$579
Takeda Pharmaceuticals U.S.A., Inc.	27	$563
Alkermes, Inc.	26	$544
Corium, LLC	22	$513
Johnson & Johnson	13	$389
Vanda Pharmaceuticals Inc.	17	$359
Bausch Health US, LLC	20	$353
Ironshore Pharmaceuticals Inc.	22	$353
Neos Therapeutics, LP	14	$342
Lundbeck LLC	16	$310
Tris Pharma Inc	12	$287
E.r. Squibb & Sons, L.L.C.	5	$281
Sunovion Pharmaceuticals Inc.	18	$263
Eisai Inc.	9	$237
Almatica Pharma LLC	9	$232
Supernus Pharmaceuticals, Inc.	14	$200
Idorsia Pharmaceuticals US Inc	4	$161
Teva Pharmaceuticals USA, Inc.	3	$149
Validus Pharmaceuticals LLC	2	$91
Alfasigma USA, Inc.	4	$78
Noven Therapeutics, LLC	4	$75
Jazz Pharmaceuticals Inc.	2	$43
Merck	3	$42
Collegium Pharmaceutical, Inc.	2	$42
Adlon Therapeutics L.p.	2	$38
Avion Pharmaceuticals	1	$17
Aytu Biopharma, Inc.	1	$8

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,221 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VraylarCariprazine Hcl	51	$81,005
RexultiBrexpiprazole	41	$78,379
CaplytaLumateperone Tosylate	13	$20,551
BelsomraSuvorexant	19	$7,791
Olanzapine	57	$2,857
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	62	$2,568
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	15	$1,927
Aripiprazole	15	$1,882
Bupropion XlBupropion Hcl	62	$1,822
Alprazolam	204	$1,795
Clonazepam	147	$1,405
Mirtazapine	77	$1,252
EpitolCarbamazepine	13	$1,093
Quetiapine Fumarate	92	$870
Prazosin Hcl	48	$861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieVraylar	$1,359	$81,00551 claims
Otsuka America Pharmaceutical, Inc.Rexulti	$661	$78,37941 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta	$1,041	$20,55113 claims
MerckBelsomra	$42	$7,79119 claims
Almatica Pharma LLCSertraline Hcl	$232	$31668 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Dallas

Cynthia TrickettDallas$1.3M
Michael WhiteDallas$276K
Sofia NeicherilDallas$62K
Shawn SommerladDallas$53K
Katherine TurnerDallas$43K
Tori BurnsDallas$39K
Suzanne RaczDallas$32K
Kristine KuceraMelissa$797K
Selina SantosAustin$543K
Matthew BrunoMcKinney$538K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →